Australia's most trusted
source of pharma news
Posted 1 July 2026 AM
An extra 1.8 million Australians will be eligible for MSD's pneumococcal vaccine after the Commonwealth expanded the age ranges and added at-risk groups. It brings the total number eligible for a funded pneumococcal vaccination to five million Australians.
"The expansion of the adult pneumococcal NIP has been long awaited, as pneumococcal disease and invasive pneumococcal disease in particular, may lead to severe illness, long-term consequences and even death," preventative health advocate, Dr Sarah Chu, said.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.